

RECEIVED

DEC 27 2001

TECH CENTER 1600/2900

#19
28
01/16/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: HU et al.

Application Serial No.: 09/257,272


Art Unit: 1647

Filed: February 25, 1999

Examiner: Landsman, R.

For: Vascular Endothelial Growth Factor 2

Attorney Docket No.: PF112P2D2



THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 CFR 1.56

Commissioner For Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the Statutory Declaration of Kari Alitalo executed on September 24, 2001 and accompanying Exhibits 1 and 2, and the Statutory Declaration of Peter Adrian Walton Rogers executed on November 12, 2001, and accompanying exhibits PAWR-1 through PAWR-14.

The above-listed declarations and accompanying exhibits were brought to the attention of the Applicants in connection with an opposition to an Australian application that essentially corresponds to the U.S. priority application in this case. A copy of the above-listed Declarations and accompanying exhibits thereto, are enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed reference(s) is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such

references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.


Applicants respectfully request that the Examiner acknowledge receipt of the enclosed Declaration and exhibits attached thereto, in the file of the instant application.

Pursuant to 37 C.F.R. § 1.97(c)(2), the Patent Office will consider this Third Supplemental Information Disclosure Statement if filed before the mailing date of a final Office Action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in this application and accompanied by the fee set forth in § 1.17(p). Accordingly, the required fee of \$180.00 is transmitted herewith with the concurrently filed Fee Transmittal, with the appropriate fee(s).

If any additional fees are deemed necessary, the Patent & Trademark Office is authorized to charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Respectfully submitted,

Dated: 12/21/01


Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5772

Enclosures
MMW/AKR/lcc